Top 4 Health Care Stocks That May Rocket Higher In Q1
Top 4 Health Care Stocks That May Rocket Higher In Q1
Read More: Beat Inflation With These 3 High-Yielding The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
醫療保健領域超賣最多的股票爲買入被低估的公司提供了機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI是一個動量指標，它比較股票在價格上漲的日子裏的走強與價格下跌的日子的走強。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數低於30時，資產通常被視爲超賣。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是該行業主要超賣參與者的最新名單，其相對強弱指數接近或低於30。
iBio, Inc. (NYSE:IBIO)
iBio, Inc.（紐約證券交易所代碼：IBIO）
- On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company's stock fell around 11% over the past five days and has a 52-week low of $1.16 .
- RSI Value: 23.25
- IBIO Price Action: Shares of iBio fell 4.9% to close at $1.17 on Friday.
- 12月5日，iBio宣佈了450萬美元公開募股的定價。該公司的股票在過去五天中下跌了約11％，並且 52 周低點爲 1.16 美元 。
- RSI 值：23.25
- IBIO價格走勢：週五，iBio的股價下跌4.9％，收於1.17美元。
GRI Bio, Inc. (NASDAQ:GRI)
GRI Bio, Inc.（納斯達克股票代碼：GRI）
- On Dec. 5, the company announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. The company's stock fell around 23% over the past month. It has a 52-week low of $0.2838.
- RSI Value: 27.58
- GRI Price Action: Shares of GRI Bio fell 3% to close at $0.3152 on Friday.
- 12月5日，該公司宣佈開始2a期生物標誌物研究的患者入組，該研究評估了用於治療IPF的 GRI-0621。該公司的股票在過去一個月中下跌了約23％。它 創下 52 周低點 爲0.2838美元。
- RSI 值：27.58
- GRI價格走勢：週五，GRI Bio的股價下跌3％，收於0.3152美元。
AlloVir, Inc. (NASDAQ:ALVR)
AlloVir, Inc.（納斯達克股票代碼：ALVR）
- On Jan. 1, 2024, AlloVir board approved a reduction its workforce by approximately 95% of current employee base to reduce costs and preserve capital. The company's stock fell around 69% over the past month and has a 52-week low of $0.6230.
- RSI Value: 28.16
- ALVR Price Action: Shares of AlloVir gained 5.3% to close at $0.6950 on Friday.
- 2024年1月1日，AlloVir董事會批准將其員工隊伍裁減約95％的現有員工隊伍，以降低成本和保留資本。該公司的股票在過去一個月中下跌了約69％，爲期52周 最低價爲0.6230美元。
- RSI 值：28.16
- ALVR價格走勢：週五，AlloVir的股價上漲5.3％，收於0.6950美元。
VYNE Therapeutics Inc. (NASDAQ:VYNE)
VYNE Therapeutics Inc.（納斯達克股票代碼：VYNE）
- On Nov. 13, VYNE Therapeutics posted a narrower-than-expected quarterly loss. "We have made substantial progress in advancing our business in recent months," said David Domzalski, President and Chief Executive Officer of VYNE. "With positive results from our Phase 1b trial, we believe there is strong support to advance VYN201 as a potential category-leading therapy in the treatment of vitiligo." The company's shares lost around 24% over the past month. The company's 52-week low is $2.00.
- RSI Value: 28.98
- VYNE Price Action: Shares of VYNE Therapeutics fell 2.8% to close at $2.06 on Friday.
- 11月13日，VYNE Therapeutics公佈的季度虧損低於預期。VYNE總裁兼首席執行官戴維·多姆扎爾斯基表示：“最近幾個月，我們在推進業務方面取得了實質性進展。”“我們的 1b 期試驗取得了積極成果，我們相信推進 VYN201 成爲治療白癜風的潛在類別領先療法得到了強有力的支持。”該公司的股價在過去一個月中下跌了約24％。該公司的52周低點爲2.00美元。
- RSI 值：28.98
- VYNE價格走勢：週五，VYNE Therapeutics的股價下跌2.8％，收於2.06美元。
Read More: Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
閱讀更多： 用華爾街最準確的分析師提供的這3只醫療保健行業高收益股息股票戰勝通脹
